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Abstract It is well established that dietary intake of n-3
fatty acids is associated with anti-inflammatory effects, and
this has been linked to modulation of the oxylipin and
endocannabinoid metabolomes. However, the amount of
data on specific tissue effects is limited, and it is not known
how inflammation affects this relation. In the present study
we systematically explored the combined effects of n-3
fatty acid diets and inflammation on the in vivo endocan-
nabinoid and oxylipin metabolomes using a multicom-
partment, detailed targeted lipidomics approach. Male
C57BL/6 mice received diets containing 0, 1, or 3 % w/w
fish oil (FO) for 6 weeks, after which 2 mg/kg LPS or
saline was administered i.p. Levels of endocannabinoids/N-
acylethanolamines (NAEs) and oxylipins, covering n-3 and
n-6 fatty acid derived compounds, were determined in
plasma, liver, ileum and adipose tissue using LC–MS/MS.
FO generally increased ‘n-3’ NAEs and oxylipins at the
expense of compounds derived from other fatty acids,
affecting all branches of the oxylipin metabolome. LPS
generally increased levels of endocannabinoids/NAEs and
oxylipins, with opposing effects across plasma and tissues.
Multivariate data analysis revealed that separation between
diet groups in the saline treated groups was primarily
explained by decreases in other than n-3 derived com-
pounds. In the LPS treated groups, the separation was
primarily explained by increases in n-3 derived com-
pounds. In conclusion, FO caused marked changes in the
n-3 to n-6 balance of the endocannabinoid and oxylipin
metabolomes, with specific effects depending on inflam-
matory status.
Keywords Endocannabinoids  Oxylipins  Fish oil 














(also abbreviated as DHET)
DiHOME Dihydroxyoctadecenoic acid
DiHoPE Dihydroxydocosapentaenoic acid








Electronic supplementary material The online version of this
article (doi:10.1007/s11306-012-0421-9) contains supplementary
material, which is available to authorized users.
M. G. J. Balvers (&)  J. Meijerink  R. F. Witkamp
Division of Human Nutrition, Wageningen University,
PO Box 8129, 6700 EV Wageningen, The Netherlands
e-mail: michiel.balvers@wur.nl
M. G. J. Balvers  K. C. M. Verhoeckx (&)  S. Bijlsma 
C. M. Rubingh  H. M. Wortelboer






















Dietary intake of long-chain n-3 polyunsaturated fatty
acids (PUFAs), like docosahexaenoic acid (DHA; 22:6
n-3) and eicosapentaenoic acid (EPA; 20:5 n-3), is known
to have beneficial health effects in both humans and
animals, which are partly explained by a reduction of
inflammatory processes (Calder 2006, 2009a; Carpentier
et al. 2006; Schmitz and Ecker 2008). The mechanisms
behind this are not completely understood, but involve
binding of n-3 PUFAs to GPR120 (Oh et al. 2010), their
conversion to resolvins (Serhan et al. 2004), and the
alteration of the eicosanoid balance (Calder 2009a).
Increased dietary intake of n-3 PUFAs leads to enhanced
incorporation of DHA and EPA in cell membranes, at the
expense of incorporation of the n-6 PUFA arachidonic
acid (ARA; 20:4 n-6). This results in decreased synthesis
of ARA-derived eicosanoids, for example PGE2, after e.g.
an inflammatory stimulus (Calder 2009b). At the same
time, increased levels of n-3 fatty acid derived eicosa-
noids are observed. These n-3 fatty acid derived metab-
olites are often referred to as ‘3-series’ or ‘5-series’
oxylipins, comprising structures like prostaglandin D3
(PGD3), PGE3, thromboxane B3 (TBXB3), and 5-hy-
droxyeicosapentaenoic acid (5-HEPE), or leukotriene B5
(LTB5), respectively (see Fig. 1 for an overview of oxy-
lipins and their origin). These compounds are in general
also pro-inflammatory, but considered less potent than the
ARA-derived metabolites under certain circumstances,
thereby contributing to a reduction of the general
inflammatory status and specific inflammatory processes
associated with fish oil (FO) consumption (Calder 2006,
2009a; Schmitz and Ecker 2008).
Over the last decades, several endocannabinoids and
related N-acyl ethanolamines (NAEs) have emerged as
important regulators of metabolism and inflammation (De
Petrocellis et al. 2000; Di Marzo 2008; Matias et al. 2006;
O’Sullivan 2007). Like the oxylipins, these compounds are
also derived from fatty acids following incorporation in
cell membranes (Bisogno 2008; Ueda et al. 2010).
Arachidonoyl ethanolamide (anandamide, AEA) and
2-arachidonoyl glycerol (2-AG) are two endocannabinoids
which are derived from ARA, but combinations derived
with other fatty acids also exist, such as palmitoyl ethan-
olamide (PEA) and the n-3 fatty acid derived NAEs
docosahexaenoyl ethanolamide (DHEA), eicosapentaenoyl
ethanolamide (EPEA). Both AEA and PEA are known for
their anti-inflammatory properties (Cencioni et al. 2010;
Re et al. 2007).
Several in vitro and animal studies have demonstrated a
link between availability of specific fatty acids in the diet
and the presence of endocannabinoids and related NAEs.
Berger and coworkers reported enhanced levels of
anandamide and 2-AG in piglet brain after feeding milk
supplemented with ARA, with a diet rich in DHA showing
even higher levels of its NAE metabolite, DHEA (Berger
et al. 2001). Wood and coworkers showed that a two-week
diet rich in DHA elevated plasma and brain levels of
DHEA in mice, while decreasing plasma 2-AG (Wood
et al. 2010). Artmann and coworkers demonstrated that
feeding rats a FO diet, by nature rich in n-3 PUFAs,
decreased jejunal levels of AEA and PEA, but increased
the levels of n-3 NAEs DHEA and EPEA (Artmann et al.
2008). Fish oil also decreased adipose tissue levels of AEA
and 2-AG in a rat model of obesity (Batetta et al. 2009). It
thus seems that the profile of NAEs represents the relative
abundance of fatty acids in the diet. Recently, is was shown
that DHEA and EPEA display anti-inflammatory properties
in macrophages and adipocytes (Balvers et al. 2010;
Meijerink et al. 2011), indicating that these compounds
might be involved in the anti-inflammatory effects which
are related to dietary n-3 PUFA intake.
In addition to diet, inflammation is known to affect the
synthesis and/or release of both oxylipins and NAEs
(Maccarrone et al. 2001), but it is not known how
inflammation itself affects e.g. DHEA and EPEA tissue
levels in vivo. Moreover, it is not known if changes
induced by dietary fatty acids also persist under inflam-
matory conditions, or if the effect of diet is different under
inflammatory conditions.
In the present study, we systematically explored in detail
the (combined) effect of dietary FO and inflammation on
levels of endocannabinoids/NAEs and oxylipins in plasma,
liver, ileum and adipose tissue of wild type C57BL/6 mice
using a targeted lipidomic approach. In total, levels on 61
compounds were analyzed, including levels of PGE3,
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PGD3, TBX-B3, 5-HEPE, resolvin D1, DHEA and EPEA.
Both univariate and multivariate data analysis tools were
used to assess differences in metabolite patterns between
the intervention groups. Our data show in detail that dietary
intake of FO shifted the n-3 to n-6 balance in the endo-
cannabinoid and oxylipin metabolomes in all tissues
examined. In addition, the direction of this shift appeared
to be affected by inflammation, and was different between
the examined tissues.
2 Materials and methods
2.1 Chemicals and reagents
Lipopolysaccharide (0111: B4; LPS), indomethacin, parao-
xon and butylated hydroxytoluene (BHT) were from Sigma
(Steinheim, Germany). Phenylmethylsulfonyl fluoride
(PMSF) was from Fluka (Steinheim, Germany). 12-[(tricy-
clo[3.3.1.13,7]dec-1-ylamino)carbonyl]amino]-dodecanoic
acid (AUDA) and URB602 was purchased from Cayman
(Ann Arbor, MI, USA). Milli-Q water (Milli-Q Advantage
unit, Millipore, Amsterdam, The Netherlands) was used in
all analyses. ULC-grade acetonitrile (ACN), formic acid
(FA) and trifluoro acetic acid (TFA) were obtained from
Biosolve (Valkenswaard, The Netherlands). LC–MS grade
methanol was from Riedel-de-Ha¨en (Steinheim, Germany).
Isopropanol and ethanol were from JT Baker (Deventer, The
Netherlands). All analytical and internal standards, except
EPEA, were purchased from Cayman. EPEA was synthe-
sized as described earlier (Plastina et al. 2009a). For oxyli-
pins, stock solutions were prepared in ethanol, aliquoted and
stored at -80 C until analysis. For endocannabinoids/
NAEs, stocks were prepared in ACN, aliquoted and stored at
-80 C until analysis. C8 SPE columns (Bond Elut; 200 mg,























































Fig. 1 Overview of several enzymatic pathways involved in oxylipin synthesis, which are under investigation in the present paper. ARA, LA,
EPA and DHA can serve as substrates, yielding distinct oxylipins and intermediates
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SPE columns (Oasis, 60 mg, 3 mL) were from Waters
(Etten-Leur, The Netherlands). ELISA kits were from R&D
Systems (Minneapolis, MN, USA).
2.2 Animal experiment
Wild type male C57BL/6 mice were obtained from Harlan
(Horst, The Netherlands) and housed two or three per cage
in a temperature controlled environment with a 12 h light–
dark cycle (light at 6.00–18.00). The mice, 4 weeks old at
arrival, had free access to a standard run-in diet (AIN93-M,
with a 4 % w/w fat content whereof 1 % soy bean oil and
3 % high-oleic acid sunflower oil (HOSF)) for 2 weeks. At
the age of 6 weeks the mice were divided into three groups
of 16 mice; group 1 was kept on the standard diet (control
diet), group 2 received a diet containing AIN93-M with
1 % fish oil (1 % FO diet) (Marinol), 2 % HOSF, and
1 % soy bean oil. The third group had access to a diet
containing AIN93-M with 1 % soy bean oil and 3 % fish
oil (3 % FO diet). The diets and water were available
ad libitum. Diets were prepared by Research Diet Services
(Wijk bij Duurstede, The Netherlands) and the Marinol
was a kind gift from Lipid Nutrition (Wormerveer, The
Netherlands). Diets were stored in air-tight bags at -20 C
until just before feeding, and fresh food was provided two
times per week to minimize oxidation of the fatty acids in
the diet. GC–MS based analysis of the diets confirmed that
the correct amounts of DHA and EPA were present, and
re-analysis after 4 weeks revealed that its amounts were
stable under the described conditions (data not shown). Food
consumption and animal weight were measured two times
per week, revealing no differences between the diet groups.
The diets were continued for 6 weeks, after which the
animals received either i.p. saline (eight mice per diet
group) or 2 mg/kg LPS (eight mice per diet group). After
24 h, the animals were anesthetized, blood was collected
from the orbital sinus and captured in 1.3 mL EDTA
coated tubes (Sarstedt; Etten-Leur, The Netherlands) and
put on ice until centrifugation (100, 10,000 rpm at 4 C).
After centrifugation, plasma was aliquoted. For oxylipin
analysis, 200 lL plasma was stored in 1 mL methanol
containing paraoxon, BHT, AUDA, indomethacin, and
PMSF to prevent oxylipin oxidation and breakdown. For
endocannabinoid/NAE analysis, 100 lL plasma was stored
in the presence of PMSF and URB602. Subsequently, the
animals were sacrificed by cervical dislocation after which
liver, ileum and adipose tissue were collected and imme-
diately snap-frozen in liquid nitrogen. All plasma and tis-
sue samples were stored at -80 C until further analysis.
Analysis of plasma IL-6 and MCP-1 levels confirmed that
LPS had triggered an inflammatory response by showing
strongly increased IL-6 and MCP-1 levels in LPS-treated
mice (data not shown).
The study was conducted according to the Netherlands
Law on Animal Experiments, and approved by the local
Animal Experiments Committee of Wageningen University.
2.3 Extraction of endocannabinoids/NAEs
from plasma
Plasma (100 lL) was thawed and 400 lL extraction mix-
ture containing 100 lM PMSF and internal standards
(AEA-d8, 2-AG-d8 and OEA-d4) in ACN was added while
the sample was gently vortexed. After subsequent centri-
fugation (5 min at 13,000 rpm and RT), the supernatant
was transferred to a clean Eppendorf tube and evaporated
to dryness in a vacuum concentrator (Scanvac; Lynge,
Denmark). The dried extracts were reconstituted in 100 lL
ACN containing 0.1 % TFA and used for LC–MS/MS
analysis.
2.4 Extraction of endocannabinoids/NAEs from tissues
Endocannabinoid/NAE were extracted from freeze–dried
liver and ileum using a method adapted from a previously
published protocol for plasma (Balvers et al. 2009).
Approximately 50 mg freeze–dried liver or 10 mg freeze–
dried ileum were extracted by adding 1 mL extraction
mixture (ACN) and sonication. The samples were centri-
fuged (5 min at 14,000 rpm), the supernatant was trans-
ferred to a clean 15 mL tube, and this was repeated once.
The pooled ACN fractions were diluted with MQ water
containing 0.13 % TFA until the final ACN concentration
was 20 % prior to SPE clean-up as described before
(Balvers et al. 2009). In short, columns were washed with
20 % v/v ACN in MQ water containing 0.1 % TFA, eluted
with 80 % v/v ACN in MQ water containing 0.1 % TFA
and evaporated to dryness using vacuum centrifugation.
The dried extracts were reconstituted in 100 lL ACN
containing 0.1 % TFA and used for LC–MS/MS analysis.
For adipose tissue, approximately 100 mg ‘wet’ tissue
was extracted with 1 mL extraction solution (ACN) by
sonication. The samples were centrifuged for 5 min at
14,000 rpm and RT, the supernatant was transferred to a
clean 2.0 mL Eppendorf tube, and the ACN extraction was
repeated once. The 2 mL ACN extract was subsequently
evaporated to dryness, reconstituted in 100 lL ACN con-
taining 0.1 % TFA and used for LC–MS/MS analysis.
2.5 LC–MS/MS analysis of endocannabinoids/NAEs
Two LC–MS/MS systems were used for endocannabinoid/
NAE analysis. Plasma extracts were analyzed by UPLC
coupled to a Xevo TQ-S mass spectrometer (Waters; Etten-
Leur, The Netherlands) because high sensitivity was essen-
tial for adequate quantification in extracts obtained from
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100 lL plasma samples. Liver, ileum and adipose tissue
were analyzed on a Surveyor HPLC coupled to a TSQ
Quantum Discovery mass spectrometer (Thermo Finnigan;
Breda, The Netherlands).
For the UPLC-Xevo system, 3 lL plasma extract was
injected on a Acquity C8 BEH UPLC column (2.1 9 100 mm,
1.7 lm) and was separated using gradient elution with a stable
flow of 500 lL/min. The gradient started with 100 % A
(40:40:20 v/v/v of MQ water:methanol:ACN with 0.1 % FA)
which was maintained until 0.35 min, followed by a linear
increase to 100 % B (7:3 v/v methanol:ACN with 0.1 % FA)
which was achieved at 7.0 min and was maintained until
9.0 min. Finally, the column equilibrated for 3 min at 100 %
A. The column was maintained at 60 C during analysis, and
the samples were kept at 10 C. The MS was operating in
selective reaction mode using electrospray ionization in
positive ion mode, with a capillary voltage of 1.5 kV, a source
temperature of 150 C and a desolvation temperature of
500 C. Cone voltage and collision energy were optimized for
each compound individually (see supplemental data S-1 for
parent and product m/z values). Peak identification and
quantification was performed using MassLynx software ver-
sion 4.1. Calibration curves were run in duplicate from which
one regression equation was generated.
For the analysis of liver, ileum and adipose tissue, a
TSQ Quantum Discovery was used as described before
(Balvers et al. 2009). Five microliters extract was separated
on an Xterra C8 MS column (2.1 9 150 mm, 3.5 lm)
using gradient elution with a constant flow of 150 lL/min.
The same solutions were used as in the Xevo system, but
now 1 g/L ammonium acetate was added (the most domi-
nant parent for 2-AG in this MS is the ammonium adduct).
The gradient started with 100 % A which was maintained
until 2.0 min, followed by a linear increase to 100 % B
which was achieved at 8.00 min and maintained until
16.0 min, and the column was left to equilibrate for 5 min
at 100 % A. The column was maintained at 40 C during
analysis and the samples were cooled at 4 C. The MS was
operating in selective reaction mode using electrospray
ionization in positive ion mode, with a capillary voltage of
4.5 kV and a capillary temperature of 350 C. Cone volt-
age and collision energy were optimized for each com-
pound individually. Peak identification and quantification
was performed using LCquan software version 2.5.5. Cal-
ibration curves were run in duplicate from which one
regression equation was generated. Quality control samples
were included in each analytical run to check the quality of
the analysis and to correct for accuracy.
2.6 Extraction of oxylipins from plasma
Internal standards were added to the plasma samples which
were already precipitated with methanol (see section ‘2.2’),
and the samples were put on ice for 30 min. Samples were
subsequently centrifuged (5 min at 3,0009g and 4 C) and
the supernatant was transferred to a glass tube. Just before
loading on activated HLB columns, 4.75 mL MQ water
containing 0.1 % v/v FA was added to the methanol extract,
diluting the extract to 20 % methanol. After loading, the
columns were washed with 2 mL 20 % methanol in MQ
water containing 0.1 % FA, and the columns were allowed to
dry for 15 min. The SPE columns were eluted with 2 mL
methanol and the samples were captured in tubes already
containing 20 lL of 10 % glycerol and 500 lM BHT in
ethanol. The tubes were placed in a water bath at 40 C and
the methanol was evaporated under a gentle stream of
nitrogen, after which the samples were reconstituted in
100 lL ethanol containing another internal standard
(CUDA) and immediately used for LC–MS/MS analysis.
2.7 Extraction of oxylipins from tissues
The extraction of oxylipins from liver, ileum and adipose
tissue was similar to plasma oxylipin extraction. Approx-
imately 100 mg liver and adipose tissue, and 50 mg ileum
was extracted with 1 mL methanol containing internal
standards and sonication. After centrifugation (5 min at
3,0009g and 4 C), the supernatants were transferred to
clean tubes and the methanol extraction was repeated once.
Just before loading on HLB SPE columns, 8 mL MQ water
containing 0.1 % FA was added to the methanol extracts.
For the SPE procedure and further, (see section ‘2.6’)
Extraction of oxylipins from plasma’.
2.8 LC–MS/MS analysis of oxylipins
All oxylipin analyses were performed on a UPLC coupled
to a Xevo TQ-S mass spectrometer (Waters). Five micro-
liters extract was injected on a Acquity C18 BEH UPLC
column (2.1 9 100 mm, 1.7 lm) and was separated using
gradient elution with a stable flow of 600 lL/min. The
gradient started with 95 % A (MQ water with 0.1 % FA)
and 5 % B (ACN with 0.1 % FA) followed by a linear
increase to 70 % A and 30 % B which was achieved at
5.0 min. This was followed by a linear increase towards
50 % B which was achieved at 11.25 min and maintained
until 13.25 min. The system was subsequently switched to
100 % B, which was achieved at 15.75 min and maintained
until 16.75 min, after which the column was left to equil-
ibrate at 5 % B for approximately 3 min. The column was
maintained at 50 C during analysis, and the samples were
kept at 10 C. The MS was operating in selective reaction
mode using electrospray ionization in negative ion mode,
with a capillary voltage of 3.3 kV, a source temperature of
150 C and a desolvation temperature of 600 C. Cone
voltage and collision energy were optimized for each
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compound individually (see supplemental data S-1 for
parent and product m/z values). Peak identification and
quantification was performed using MassLynx software
version 4.1. Calibration curves were run in duplicate from
which one regression equation was generated. During data
analysis, five peaks of unknown identity were found to be
influenced by diet or LPS treatment, and these compounds
are listed UK1–UK5. These peaks were visible in the
transitions m/z 295.2 [ 195.2 and m/z 295.2 [ 171.1.
ARA, DHA and EPA were also determined using this
method. Quality control samples were included in each
analytical run to check the quality of the analysis and to
correct for accuracy.
2.9 Data analysis
Univariate analysis was performed with SAS version 9.1
(2002–2003 by SAS Institute Inc., Cary, NC, USA).
ANOVA assumptions were checked for each variable. If
these assumptions were not met, rank transformation was
applied for that particular variable. Partial tests were per-
formed using Tukey–Kramer multiple comparison correc-
tion. Benjamini and Hochberg false discovery rate
correction (q = 5 %) was applied to correct for false
positives (Benjamini and Hochberg 1995). In all statistical
tests that were performed, the null hypothesis (no effect)
was rejected at the 0.05 level of probability (a = 5 %).
The added value of multivariate data analysis in addition
to univariate statistics is that correlations between variables
are taken into account, and thus also allows to reveal
combinations of variables which are associated with dif-
ferences between treatment groups. Multivariate data
analysis summarizes all the variables into one variable by
means of a linear combination, now called the ‘principal
component’ (PC), which adds higher weights to variables
that account for the highest level of variance in the original
data. Using principal component analysis (PCA), we
screened for group separation, outliers, (undesired) patterns
and this was further analyzed with principal component
discriminant analysis (PCDA). PCDA includes the original
group designation of the animals in the model and is
therefore called a supervised classification technique. PCA
and PCDA were performed in the Matlab environment
(R2008b, 1984–2008, The Mathworks Inc., Natick, MA,
USA) using the PLS toolbox for Matlab version 5.0.3
(r 6466, 1995–2008, Eigenvector Research Inc., Wenatchee,
WA, USA). PCA and PCDA are described in more detail
elsewhere (Hoogerbrugge et al. 1983; Joliffe 1986). For all
multivariate models data were autoscaled to mean zero and
variance 1 for each variable. For PCDA, stability of the
model was evaluated by 10-fold cross-validation, revealing
correct classification rates of typically 80–100 %. PCA and
PCDA were performed on the combined data (‘fused
data’), containing data on both endocannabinoids/NAEs
and oxylipins from plasma, liver ileum and adipose tissue
combined in one data set.
3 Results
3.1 FO diet and inflammation alter
the endocannabinoid/NAE balance
To investigate the effect of dietary n-3 fatty acids and
inflammation on endocannabinoid/NAE and oxylipin lev-
els, wild-type male C57BL/6 mice received a diet con-
taining either no, 1 or 3 % w/w FO followed by either
saline or 2 mg/kg LPS i.p. injection. Endocannabinoid/
NAE levels were determined in plasma, liver, ileum and
adipose tissue.
Detailed (quantitative) effects of dietary administration
of fish-oil and administering LPS after 6 weeks compared
to their relevant control treatments are provided in the
supplemental data (S2-7), including some representative
chromatograms (S-8). Significant differences between diet
groups and LPS treatment were obtained with the ANOVA
test and are summarized in Tables 1, 2 for endocannabi-
noids/NAEs and Tables 3, 4 for oxylipins. A diet effect is
here defined as an effect of the diet which (in magnitude
and direction) was the same for saline and LPS-treated
mice. The term LPS effect refers to situations in which LPS
induced a change in a concentration of a compound, which
was similar for all diet groups. An interaction effect indi-
cates that only certain (combinations of) diets with saline
or LPS resulted in significant differences, and therefore
separate comparisons (‘partial tests’) should be interpreted
rather than main effects. Table 1 shows diet effects on
NAEs/endocannabinoids, and 2 LPS effects. Compounds
with an interaction effect are highlighted with * in the
tables, with further details provided in the supplemental
data (S-5).
The FO diets altered endocannabinoid levels with dif-
ferent effects in plasma, liver, ileum and adipose tissue
(Table 1). DHEA was increased by both FO diets in all
compartments compared to control diet. For EPEA, an
interaction effect (see supplemental data) was observed in
liver, but the compound was increased by the FO diets in
plasma, ileum and adipose tissue. The endocannabinoids/
NAEs derived from other fatty acids, such as AEA and
2-AG, were in general decreased by the FO diets, but some
deviations were observed. For instance, 2-AG levels in
adipose tissue and liver were decreased in both FO groups
compared to the control diet. When comparing the 1 %
versus the 3 % FO group, liver 2-AG was lower in the 3 %
group, but higher in adipose tissue. DGLEA (also known as
DLE) in liver was not influenced by the diets, but was
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decreased in plasma, ileum and adipose tissue in the FO
groups. OEA was decreased in liver and plasma, but not in
ileum. When comparing the control diet group with the
3 % FO group, SEA displayed opposite effects in adipose
tissue and plasma; FO was found to decrease plasma levels,
but increased adipose tissue levels of SEA. This was also
observed when comparing the 1 % versus the 3 % FO
groups.
The effect of LPS on endocannabinoids appeared to be
both compound and tissue specific (Table 2; for effects of
LPS on endocannabinoids for each diet group, please refer
to the supplemental data). LPS increased DHEA levels in
all compartments, but for some compounds tissue-specific
effects were seen. LPS decreased plasma 2-AG, whereas it
increased adipose tissue 2-AG. A similar divergence is
seen for SEA and PEA. LPS increased plasma and ileum
Table 1 Effect of the fish oil diets on endocannabinoid/NAE levels in plasma, liver, ileum and adipose tissue (diet effect)
Plasma Liver Ileum Adi. tiss.
Ctrl vs 1 % FO n-3 derived EPEA 2.51 * 24.159 43.096
DHEA 1.915 2.908 2.123 3.241
Other AEA * 0.312 0.374 0.350
2-AG 0.403 0.216 0.304 0.465
DGLEA 0.282 – 0.650 0.562
OEA 0.710 0.777 – *
Ctrl vs 3 % FO n-3 derived EPEA 3.688 * 67.069 116.975
DHEA 2.166 4.691 2.774 5.484
Other AEA * – 0.811 0.423
2-AG 0.301 0.156 0.272 0.607
DGLEA 0.250 – ; 0.578
OEA 0.522 0.663 – *
SEA 0.692 – – 1.574
1 % FO vs 3 % FO n-3 derived EPEA – * 2.776 2.714
DHEA – 1.613 1.306 1.692
Other 2-AG – 0.724 – 1.304
OEA 0.735 – – *
SEA 0.700 – – 1.284
Only statistically significant effects are listed, presented as fold-control values, calculated by comparing mean metabolite concentration from one
diet to another. Means were calculated from saline and LPS treated animals together per diet group. : or ; were used when the fold-control value
would disagree with the outcome outcome of the ANOVA in cases of variables which were rank-transformed
ND the compound was not detected in the particular matrix, and – indicates that no statistical significant differences were observed
* Interaction effect (see supplemental data for details)
Table 2 Effect of LPS on endocannabinoid/NAE levels in plasma, liver, ileum and adipose tissue (LPS effect)
Plasma Liver Ileum Adi. tiss.
Saline vs LPS n-3 derived EPEA 2.019 * – 1.766
DHEA 2.101 4.130 1.338 1.584
Other AEA * 3.375 1.274 –
2-AG 0.651 – – 1.366
DGLEA 1.961 1.611 : –
PEA * 0.743 1.406 *
OEA 3.097 2.276 1.260 *
SEA 2.073 0.540 1.676 0.711
Only statistically significant effects are listed, presented as fold-control values, calculated by comparing mean metabolite concentration from the
saline to the LPS treated groups. Means were calculated from the different diet groups together for the saline and LPS treated animals. : or ;
were used when the fold-control value would disagree with the outcome outcome of the ANOVA in cases of variables which were rank-
transformed
ND the compound was not detected in the particular matrix, and – no statistical significant differences were observed
* Interaction effect (see supplemental data for details)
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Table 3 Effect of the fish oil
diets on oxylipin levels in
plasma, liver, ileum and adipose
tissue (diet effect)
Plasma Liver Ileum Adi. tiss.
Ctrl vs 1% FO
Fatty acids
ARA * 0.326 – 0.520
DHA 1.931 – 2.128 –
EPA * 13.93 24.182 29.425
n-3 derived oxylipins
5-HEPE 4.358 7.474 9.459 34.105
12-HEPE * 4.753 19.379 24.735
PGD3 ND ND 18.828 3.937
PGE3 – ND 15.534 12.614
17-HDoHE – – 3.014 2.694
10-17-DiHDoHE ND ND 2.566 3.352
19,20-DiHoPE 3.040 1.534 2.381 4.447
TBXB3 * ND 20.657 4.809
n-6 oxylipins
5,6 EET – 0.163 – –
11,12 EET – 0.293 0.495 0.484
14,15 EET 0.492 0.319 0.476 0.497
LTB4 ND 3.356 0.470 *
LTD4 ND ND 0.184 –
5,6-DiHETrE – 0.215 0.392 0.383
8,9-DiHETrE 0.314 0.213 0.378 *
11,12-DiHETrE 0.280 0.249 0.419 0.378
14,15-DiHETrE 0.327 0.251 0.404 *
PGE2 – 0.205 – –
PGF2a – 0.234 – –
8-iso-PGF2a – – – 0.629
13,14-dihydro-15-keto-PGD2 ND ND 0.292 ND
13,14-dihydro-15-keto-PGE2 ; 0.373 0.242 0.198
13,14-dihydro-15-keto-PGF2a ND 0.432 0.255 0.473
12-HHTrE – 0.107 – 0.298
5-HETE 0.416 0.410 – 0.632
11-HETE – 0.233 – 0.417
12-HETE – 0.150 – –
15-HETE – 0.211 – 0.252
20-HETE ND 0.419 – ND
TBXB2 – 0.209 – –
13-HODE – 0.570 – –
9,10,13-TriHOME – * – 0.686
Ctrl vs 3% FO
Fatty acids
ARA * 0.302 – –
DHA 1.642 – 2.828 –
EPA * 19.597 37.806 54.972
17 keto- 4(z), 7(z), 10(z),
13 (z), 15 (E), 19(z)-DHA
ND – 2.830 *
n-3 derived oxylipins
5-HEPE 7.430 12.323 19.378 163.982
12-HEPE * 7.684 33.107 55.445
PGD3 ND ND 14.818 9.352
PGE3 – ND 23.562 32.107
17-HDoHE – 2.051 3.362 3.148
10-17-DiHDoHE ND ND 3.384 4.768
19,20-DiHoPE 5.717 2.244 4.172 18.053
TBXB3 * ND 16.198 10.438
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Table 3 continued
Only statistically significant effects
are listed, presented as fold-control
values, calculated by comparing mean
metabolite concentration from one
diet to another. Means were
calculated from saline and LPS
treated animals together per diet
group. : or ; were used when the
fold-control value would disagree
with the outcome outcome of the
ANOVA in cases of variables which
were rank-transformed
ND the compound was not detected in
the particular matrix, and ‘–’ indicates
that no statistical significant
differences were observed
* Interaction effect (see supplemental
data for details)
Plasma Liver Ileum Adi. tiss.
Other oxylipins
5,6 EET – 0.120 – –
8,9 EET ND ND 0.329 –
11,12 EET 0.512 0.179 0.489 0.566
14,15 EET 0.492 0.277 0.537 –
LTB4 ND 3.524 0.357 *
LTD4 ND ND 0.184 –
n-acetyl-leukotriene E4 ND 0.628 * ND
5,6-DiHETrE 0.358 – 0.246 0.496
8,9-DiHETrE 0.481 0.186 0.328 *
11,12-DiHETrE 0.303 0.221 0.388 0.593
14,15-DiHETrE 0.562 0.224 0.366 *
PGD2 0.363 * – –
PGE2 0.397 0.229 – –
PGF2a – 0.259 – –
8-iso-PGF2a – – – 0.623
13,14-dihydro-15-keto-PGD2 ND ND 0.180 ND
13,14-dihydro-15-keto-PGE2 0.479 0.275 0.157 0.244
13,14-dihydro-15-keto-PGF2a ND 0.240 0.200 0.405
12-HHTrE 0.421 0.094 – 0.224
5-HETE 0.375 – – –
11-HETE 0.401 0.094 – –
12-HETE 0.265 0.159 – 0.289
15-HETE 0.323 0.250 – 0.234
20-HETE ND 0.447 – ND
TBXB2 0.403 0.215 – –
9-HODE – – – 0.417
13-HODE 0.559 ; – 0.308
lipoxin A4 ND 1.771 2.533 7.181
1% FO vs 3% FO
Fatty acids
DHA – – 1.329 –
EPA * – 1.563 1.868
17 keto- 4(z), 7(z), 10(z),
13 (z), 15 (E), 19(z)-DHA
ND – 1.786 *
n-3 derived oxylipins
5-HEPE – 1.649 2.049 4.808
12-HEPE * – 1.708 2.242
PGD3 ND ND – 2.545
PGE3 – ND – 2.375
17-HDoHE – 1.435 – –
19,20-DiHoPE – 1.463 - 4.060
Other oxylipins
5-HETE – – 0.416 1.739
11-HETE 0.487 – – –
13-HODE 0.651 – – –
15-HETE 0.442 – – –
PGE2 0.492 – – –
13,14-dihydro-15-keto-PGE2 – – 0.648 –
13,14-dihydro-15-keto-PGF2a ND 0.555 – –
lipoxin A4 ND 2.075 2.877 6.588
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SEA levels, but decreases liver and adipose tissue SEA
levels. PEA levels were decreased in liver by LPS, but
increased in ileum.
In summary, both the FO diets and the LPS treatment
affected plasma and tissue endocannabinoid/NAE levels. In
general, DHEA and EPEA were increased by the FO diets,
and compounds derived from other fatty acids were
decreased, with different effects for 1 and 3 % FO diets.
LPS raised endocannabinoid/NAE levels in general, but
opposing effects were seen for 2-AG, PEA and SEA across
the tissues investigated.
3.2 FO diet and inflammation alter the oxylipin balance
The results of the oxylipin analyses in plasma, liver, ileum
and adipose tissue are presented in Tables 3 and 4, with
Table 4 Effect of LPS on oxylipin levels in plasma, liver, ileum and adipose tissue (LPS effect)
Plasma Liver Ileum Adi. tiss.
Saline vs LPS Fatty acids ARA * 1.827 – 1.854
DHA 2.033 1.590 – –
EPA * – – 1.791
n-3 derived oxylipins 5-HEPE 2.049 – – 5.626
PGD3 ND ND – 2.498
PGE3 – ND 3.256 4.217
10(S)-17(S)-DiHDoHE ND ND – 2.249
19,20-DiHoPE 3.886 1.376 1.874 3.822
TBXB3 * ND 2.637 4.752
Other oxylipins 5,6 EET – – – 2.847
11,12 EET – – – 1.843
14,15 EET – 1.890 – –
LTB4 ND 0.538 – *
LTD4 ND ND – 2.445
n-acetyl leukotriene E4 ND 1.627 * ND
5,6 DiHETrE – – – 1.744
8,9-DiHETrE 2.170 – – *
11,12-DiHETrE 2.167 – – –
14,15-DiHETrE 1.943 – – *
PGE2 1.958 2.449 – 2.039
PGF2a – – – 1.777
8-iso-PGF2a – 1.778 – –
13,14-dihydro-15-keto-PGE2 2.600 – – 1.243
13,14-dihydro-15-keto-PGF2a ND 1.815 – –
12-HHTrE 0.201 – – 2.252
5-HETE 2.240 – – 2.435
11-HETE 0.561 1.887 – 1.925
12-HETE – 0.782 – –
15-HETE 0.433 – – –
20-HETE ND 2.399 – ND
TBXB2 0.175 – 2.560 2.277
9-HODE 1.267 – 2.768 2.014
13-HODE – – 2.086 1.206
9,10,13-TriHOME 1.301 * – –
Lipoxin A4 ND – – 2.372
Only statistically significant effects are listed, presented as fold-control values, calculated by comparing mean metabolite concentration from the
saline to the LPS groups. Means were calculated from the different diet groups together for saline and LPS treated animals.
ND the compound was not detected in the particular matrix, and – indicates that no statistical significant differences were observed
* Interaction effect (see supplemental data for details)
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Table 3 showing diet effects and Table 4 LPS effects.
Compounds with an interaction effects are highlighted with
an * in the tables, with details provided in the supplemental
data (S-5 and S-6). UK compounds are not presented in
Table 5, but can be found in the supplemental data.
The FO diets decreased levels of ARA and increased
DHA and EPA, confirming that the increased dietary intake
of n-3 fatty acids was reflected in tissue fatty acid levels
(Table 3). Furthermore, n-3 derived oxylipin levels were
increased by the FO diets, with the most pronounced
effects observed in ileum and adipose tissue. The oxylipins
derived from other fatty acids were in general decreased by
the FO diets, with some exceptions, and effects were not
always consistent over all tissues tested. Levels of LTB4
were decreased in ileum and adipose tissue by the FO diets,
but liver levels were increased. Lipoxin A4 levels were
increased in the 3 % FO group compared to the control and
1 % FO diet in liver, ileum and adipose tissue. When
comparing the 1 and 3 % FO diets, ileal 5-HETE levels
were decreased in the 3 % FO group, but its level was
increased in adipose tissue. The FO diets decreased oxy-
lipins belonging to different branches of the fatty acid
oxylipin cascade, including the cyclooxygenase pathway
(COX; PGD2, PGE2 and their metabolites 13,14-dihydro-15-
keto-PGD2 and –PGE2, PGF2a, TBXB2), the 15-lipo-oxy-
genase pathway (15-LOX; 15-HETE), 12-LOX (11-HETE
Table 5 Top lists generated from PCA analysis
PC1 PC2
P_AEA 0.13562 F_pea 0.148486
P_AA 0.128696 L_dhea 0.141097
P_DLE 0.12706 F_TBXB3 0.138751
L_13,14-dihydro-15-keto-PGF2a 0.120315 P_DHEA 0.137637
L_AA 0.12015 P_19,20-DiHoPE 0.137193
L_2-ag 0.116734 F_UK3 0.136532
P_11,12-DiHETrE 0.116219 F_5(S)-HETE 0.136382
L_8,9-DiHETrE 0.115152 F_17 keto- 4(z), 7(z), 10(z), 13 (z), 15 (E), 19(z)-DHA 0.135592
I_13,14-dihydro-15-keto-PGE2 0.114106 F_PGE3 0.133149
I_2-ag 0.113331 F_19,20-DiHoPE 0.133074
L_15(S)-HETE 0.112971 F_oea 0.132124
F_aea 0.112488 F_UK5 0.131976
L_EPA -0.11245 F_UK2 0.128994
L_14,15 EET 0.111192 I_PGE3 0.128277
L_5(S)-HEPE -0.11066 F_UK4 0.127957
L_11(S)-HETE 0.10907 P_DHA 0.127188
P_14,15-DiHETrE 0.107335 F_AA 0.125684
I_13,14-dihydro-15-keto-PGF2a 0.105203 F_5(S)-HEPE 0.12297
P_8,9-DiHETrE 0.104781 I_19,20-DiHoPE 0.121367
L_11,12 EET 0.103724 F_12,13-DiHOME 0.12071
I_13,14-dihydro-15-keto-PGD2 0.100174 P_PEA 0.120517
L_PGE2 0.100147 P_12,13-DiHOME 0.118135
I_12(S)-HEPE -0.09961 F_lipoxin A4 0.115389
F_2-ag 0.099293 P_EPEA 0.115294
L_14,15-DiHETrE 0.098683 F_5,6 EET 0.115132
L_12(S)-HHTrE 0.098509 F_PGD3 0.114641
I_EPA -0.09806 F_dhea 0.113431
F_dle 0.09791 L_epea 0.112967
F_13,14-dihydro-15-keto-PGF2a 0.097779 P_9,10-DiHOME 0.11289
F_EPA -0.09662 F_9,10-DiHOME 0.109149
The D-scores represent the variable’s weight in the separation, and is expressed as the numerical output value as obtained from the PCA model;
the further away from zero, the better this variable accounts for group separation. PC1 separated the diets, whereas PC2 separated between saline
and LPS treatment
P plasma, L liver, I ileum, F adipose tissue
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and 12-HETE), 5-LOX (5-HETE, LTB4 and LTD4) and the
cytochrome P450 pathways (EETs and DiHETrEs) (see
Fig. 1 for an overview).
Treatment with LPS generally resulted in increased
levels of fatty acids, n-3 derived oxylipins and other oxy-
lipins, with the most compounds affected in plasma and
adipose tissue, and the least number of compounds altered
in ileum (Table 4; for effects of LPS on oxylipins for each
diet group, please refer to the supplemental data). Again,
opposing effects were observed between compartments for
some components. LPS decreased plasma levels of
11-HETE, but increased liver levels. TBXB2 was decreased
by LPS in plasma, but increased in ileum and adipose
tissue. Effects on UK compounds are listed in the supple-
mental data.
3.3 Multivariate data analysis shows separation
between diet groups and LPS treatment
The univariate data analysis approach revealed that both
FO and LPS altered endocannabinoid/NAE and oxylipin
levels, and effects were seen in plasma, liver, ileum and
adipose tissue. In total, 244 variables obtained in four
compartments were evaluated, which were, due to com-
plexity, further analyzed with multivariate data analysis to
evaluate differences between treatment groups. Two
methods were used, the unbiased PCA and the supervised
PCDA. In the PCA plot (Fig. 2), a good separation of the
six intervention groups can be seen. PC1 separated the
diets, with negative loadings associated to n-3 fatty acid
derived metabolites, and positive loadings belonging to
other metabolites. From the top-30 variables relevant for
group separation in PC1 (see Table 5), 13 variables were
from liver, whereas plasma, ileum and adipose tissue were
equally important. In total four metabolites were derived
from n-3 fatty acids, and 26 were derived from other fatty
acids. PC2 separated between saline and LPS treatment,
containing equal numbers of n-3 derived- and other
metabolites. From the top-30 variables accounting in PC2,
19 metabolites were from adipose tissue, with 15 n-3 fatty
acid derived metabolites, and 15 derived from other fatty
acids.
3.4 The diet effect in the saline treated mice is
explained by other variables than the diet effect
in the LPS-treated mice
To further explore differences between diet groups, PCDA
was performed. The data was split for saline and LPS-
treated mice, thus resulting in two separate PCDA plots.
PCDA analyses showed that there is separation based on
diet for both the saline and LPS-treated mice (Fig. 3). The
contribution of a variable in the PCDA model is expressed
as its D-score, with a positive score meaning an increase by
the FO diets, and a negative score indicating a decrease.
Analysis of D-scores focused on the 50 compounds with
the highest D-scores as there was considerable decay in
D-score values between the first and 50th compound,
meaning that any differences within this range can be
considered as a potentially meaningful difference. The
analysis revealed that the diet groups are separated by
increased levels of n-3 derived compounds in the FO
groups, and compounds derived from other fatty acids were
generally decreased by the FO diets (Table 6). In addition
to this, both endocannabinoids/NAEs and oxylipins show
up in the top of the rank lists, indicating that both classes of
compounds are important to describe the diet effect. The
ranking, number and origin of n-3 derived metabolites in
the models is different between the saline and LPS treated
animals. Out of the 50 compounds ranking highest for the
saline treated mice, only 12 compounds are n-3 fatty acid
derived metabolites, while for the LPS treated mice, the
top-50 list contains 25 n-3 fatty acid derived metabolites.
In addition to this, the majority of n-3 derived compounds
in the LPS treated mice from this list originated from
adipose tissue.
From these results, it can be concluded that the diet
effect of FO in the saline treated animals is mainly
explained by a decrease of compounds derived from other
than n-3 fatty acids, and to a lesser extent by an increase of
n-3 derived metabolites. However, for the LPS treated
mice, the diet effect is principally explained by an increase
of n-3 derived metabolites, and to a lesser extent by a
decrease of metabolites derived from other than n-3 fatty
acids.


































Fig. 2 PCA analysis on fused data. The PCA plot shows good
separation of the three diet groups. PC1 describes mainly the diet
effect, and PC2 mainly the LPS effect
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4 Discussion
Our results support the general idea that increasing dietary
n-3 fatty intake results in increased levels of n-3 derived-
endocannabinoids/NAEs and oxylipins. However, to the
best of our knowledge, our study is the first one describing
effects of dietary FO on the balance between the ‘‘endo-
cannabinoid’’ and oxylipin pathways in such detail, in
different compartments simultaneously, and in relation
with inflammation. In addition, our study illustrates the risk
of obtained potentially premature conclusions when only a
few mediators are analyzed in a limited number of matri-
ces. Several studies, focusing on for example AEA
(anandamide) and 2-AG only, have concluded that dietary
FO leads to an overall down regulation of the endocan-
nabinoid system (Banni et al. 2011; Batetta et al. 2009).
However, as we show other (n-3 derived-) endocannabi-
noids might be affected in an opposite direction following
FO intake, and our data shows that the sum of all NAE
levels in liver, ileum and plasma are actually quite stable
with the different diets (data not shown). Although there
are still several questions regarding their biological role,
there are reports showing that n-3 derived ethanolamides
have affinity for CB1 and CB2 receptors (Brown et al.
2010; Plastina et al. 2009b), and have anti-inflammatory
properties (Balvers et al. 2010; Meijerink et al. 2011).
LPS was found to produce a general increase of in vivo
endocannabinoid/NAE and oxylipin levels, although there
were some exceptions (see below). Multivariate data
analysis showed that the diet effect was also present during
inflammatory conditions. Without LPS, the effect of a FO
diet was mainly explained by a reduction of mediators
other than those derived from n-3 fatty acids, and to a
lesser degree by increased levels of n-3 derived
metabolites. However, after LPS, the balance was shifted in
favor of an increase of n-3 derived mediators while lower
associations were found with reductions of non n-3 derived
metabolites.
The relation between dietary fatty acid intake and the
presence of endocannabinoids/NAEs and oxylipins in
plasma and tissues has been established before (Banni and
Di Marzo 2010; Hansen and Artmann 2008), but not under
conditions of inflammation. Previous work with rats dem-
onstrated that patterns of organ levels of NAEs follow the
relative abundance of fatty acids in the diet (Artmann et al.
2008). Other work, investigating the effect of DHA on
murine levels of endocannabinoids/NAEs in brain and
plasma, showed strongest changes in plasma (Wood et al.
2010). Interestingly, plasma AEA levels were not signifi-
cantly affected by DHA alone, whereas other NAEs were
decreased by DHA. Other work, supplementing krill oil or
menhaden oil to human subjects also did not show an effect
on plasma AEA levels (Banni et al. 2011). Our work shows
that 6 weeks of a FO diet is capable of reducing plasma
AEA and 2-AG levels. This discrepancy might originate
from differences in n-3 fatty acids sources, daily dose, or
length of the period in which the n-3 fatty acids were
supplemented.
Many studies analyze plasma levels of endocannabi-
noids/NAEs or oxylipins. The present work shows that
plasma levels do not always reflect effects in liver, ileum or
adipose tissue. For example, plasma 2-AG levels decreased
after LPS, but were increased in adipose tissue, and similar
divergences were also observed for PEA, SEA, several
HETEs, and TBXB2. The origin and significance of these
findings are not known yet, but this could be related to
synthesis, release, uptake or breakdown which might be
differentially regulated by LPS or other factors across

























































































Fig. 3 PCDA analysis, split for saline and LPS treated mice. A separation of diet groups is observed in both saline and LPS treated mice, with a
more prominent separation in the LPS treated mice
1142 M. G.J. Balvers et al.
123
Table 6 Top lists for saline and LPS treated mice. Lists were generated from PCDA analysis, showing different patterns for saline and LPS
treated mice
Saline D-score LPS D-score
P_AEA -4,6879 L_2-AG -4,3994
L_2-AG -4,5742 P_AEA -4,2737
P_DGLEA -4,5412 1 F_EPA 4,2374
F_AEA -4,4914 2 F_12-HEPE 4,1634
P_ARA -4,4486 3 P_EPA 4,1441
P_11,12-DiHETrE -4,4257 P_2-AG -4,1053
1 F_DHEA 4,3978 P_AA -4,0854
P_14,15-DiHETrE -4,3961 4 I_PGE3 4,0450
L_ARA -4,3915 5 F_TBXB3 4,0374
L_13,14-dihydro-15-keto-PGF2a -4,3025 6 F_PGE3 3,9827
L_12-HETE -4,2590 P_DGLEA -3,9498
F_8,9-DiHETrE -4,2553 L_14,15-DiHETrE -3,8977
L_15-HETE -4,2343 7 F_DHEA 3,8946
2 L_5-HEPE 4,2162 8 I_EPA 3,8541
L_11-HETE -4,1548 9 L_EPEA 3,7505
3 L_EPA 4,1323 L_11,12-DiHETrE -3,7410
4 P_EPA 4,1269 10 L_DHEA 3,7222
F_DGLEA -4,1166 L_ARA -3,6999
P_8,9-DiHETrE -4,0892 11 L_EPA 3,6953
I_13,14-dihydro-15-keto-PGE2 -4,0783 12 I_DHA 3,6912
P_OEA -4,0592 13 I_12-HEPE 3,6874
F_11,12 EET -4,0186 L_8,9-DiHETrE -3,6672
F_OEA -4,0148 14 F_EPEA 3,6327
L_8,9-DiHETrE -4,0079 L_13,14-dihydro-15-keto-PGF2a -3,6261
I_2-AG -3,9897 I_2-AG -3,6231
F_9,10-DiHOME -3,9147 15 P_DHA 3,5903
P_9,10-DiHOME -3,8645 F_AEA -3,5678
L_LTB4 3,8175 L_PGD2 -3,5455
F_11,12-DiHETrE -3,7600 16 F_PGD3 3,5197
F_14,15-DiHETrE -3,7376 17 F_19,20-DiHoPE 3,5168
L_5,6 EET -3,7094 L_AEA -3,5158
I_13,14-dihydro-15-keto-PGF2a -3,7008 18 I_19,20-DiHoPE 3,4924
P_12,13-DiHOME -3,6962 L_14,15 EET -3,4871
F_12,13-DiHOME -3,6718 19 I_EPEA 3,4515
5 P_DHEA 3,6677 20 I_5-HEPE 3,4391
P_UK4 -3,6605 I_AEA -3,4310
L_14,15 EET -3,6511 F_SEA 3,4187
6 F_EPA 3,6069 L_20-HETE -3,4104
7 I_19,20-DiHoPE 3,5938 I_13,14-dihydro-15-keto-PGE2 -3,3956
F_5,6-DiHETrE -3,5357 21 P_5-HEPE 3,3787
P_2-AG -3,5155 22 L_5-HEPE 3,3617
8 I_12-HEPE 3,4899 L_TBXB2 -3,3200
L_11,12 EET -3,4781 L_12-HHTrE -3,3155
9 F_EPEA 3,4723 P_5,6-DiHETrE -3,3080
10 L_19,20-DiHoPE 3,4679 23 F_5-HEPE 3,3048
L_12-HHTrE -3,4525 24 P_DHEA 3,2978
P_UK2 -3,4144 P_11,12-DiHETrE -3,2966
L_PGE2 -3,4143 25 F_17 keto- 4(z), 7(z), 10(z), 13 (z), 15 (E), 19(z)-DHA 3,2931
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different organs. Nevertheless, based on our results,
extrapolating effects found in plasma to effects on
peripheral tissues is not always appropriate. It should be
noted that the recovery of endogenous metabolites from
tissues might not be complete, potentially underestimat-
ing actual effects of the diet and inflammation in the
tissues.
The LPS treated mice had a lower food intake combined
with a small loss of body weight (data not shown), whereas
the saline treated animals displayed normal food con-
sumption and stable body weight. Previous work showed
that levels of endocannabinoids and related NAEs depend
on fasting status (Hansen and Diep 2009; Joosten et al.
2010; Li et al. 2011); their tissue levels being high during
fasting, followed by a rapid postprandial decrease. Possi-
bly, the effect of LPS on endocannabinoid levels might in
part be mediated through such a ‘fasting’ effect. In addi-
tion, inflammation reduces FAAH expression, and inhibi-
tion of FAAH or monoacyl glycerol lipase (MGL) has been
shown to reduce disease symptoms in several models of
inflammation (Alhouayek et al. 2011; Maccarrone et al.
2001; Naidu et al. 2010). Similarly, studies using CB2
knock-out models under induced inflammatory conditions
showed that increased levels of NAEs likely contribute to
suppress inflammation (Ba´tkai et al. 2007). Together, this
suggests that increased levels of endocannabinoids/NAEs
are part of a normal response protecting against inflam-
matory stress. Previous work identified DHEA and EPEA
as having anti-inflammatory properties in macrophages and
adipocytes (Balvers et al. 2010; Meijerink et al. 2011), and
these compounds could be another link between FO and its
anti-inflammatory effects as n-3 derived NAEs were more
effective than AEA in suppressing nitric oxide release from
macrophages (Meijerink et al. 2011).
The FO diets also influenced levels of oxylipins,
including metabolites from the COX, CYP450, and
5-LOX, 12-LOX and 15-LOX pathways (Fig. 1), and these
effects were in general also seen during inflammatory
conditions. Another strength of the present study is that we
analyzed both n-6 and n-3 related oxylipins simultaneously
in different compartments. In general, levels of n-3 fatty
acid derived oxylipins (e.g. PGD3, PGE3, 5-HEPE,
12-HEPE and TBXB3) were increased with FO at the
expense of oxylipins derived from other fatty acids (e.g.
PGD2, PGE2, PGF2a, TBXB2 and members of the EET and
HETE subclasses). A functional role in inflammation has
been described for several of these compounds, and it is
likely that the changes in profiles which are found in this
study (and before) are causally related to the anti-inflam-
matory effects which are associated with n-3 fatty acid
intake. For example, PGE3 is less potent than PGE2 in
inducing COX-2 expression and IL-6 release (Bagga et al.
2003). A similar principle applies to the thromboxanes
(Fischer and Weber 1983; von Schacky et al. 1985) and for
5-HETE/5-HEPE (Heidel et al. 1989), which were also
altered by the FO diets.
Interestingly, the FO diets increased liver LTB4 levels,
whereas ileum LTB4 levels were decreased. LTB4 has
multiple pro-inflammatory functions in the immune system
(Calder 2003), but the different effect of FO on organ
levels of LTB4 is not understood. Lipoxin A4, a compound
with anti-inflammatory properties (Schwab and Serhan
2006), was increased by the 3 % FO diet. This indicates
that at least for this compound, which is synthesized from
ARA, its levels are not directly related to dietary supply of
precursors, but that other presently unknown factors are
involved.
Levels of several EETs were reduced by the FO diets,
especially in the liver. EETs play regulatory roles in heart
and vascular physiology with effects on blood pressure
regulation, but also have anti-inflammatory effects (Spector
2009). It thus seems that EETs do not play a role in the
anti-inflammatory properties of n-3 fatty acids, but it
should be noted that n-3 fatty acid derived EET analogues
are reported to be endogenously present and have potent
analgesic properties (Morisseau et al. 2010), but these
specific EETs were not quantified in the current study.
Another line of evidence suggests that EETs very specifi-
cally alter the release of either insulin or glucagon (Falck
et al. 1983; Sacerdoti et al. 2003), pointing to a potential
link between n-3 fatty acids and glucose metabolism. EETs
might therefore also be part in mediating effects of dietary
Table 6 continued
Saline D-score LPS D-score
11 I_EPA 3,3758 L_11-HETE -3,2792
12 P_5-HEPE 3,3581 P_15-HETE -3,2618
The D-scores represent their weight, expressed as the numerical output value as obtained from the PCDA model; the further away from zero, the
better this variable accounts for group separation. Negative scores indicate that the compound is decreased in the fish oil groups; positive scores
mean that it is increased by fish oil. Decrease of other than n-3 derived compounds ranks relatively high in the saline diet effect, whereas an
increase in n-3 derived compounds (printed in bold) ranks high for the diet effect in the LPS treated mice
P plasma, L liver, I ileum, F adipose tissue
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fatty acids on metabolism, but this relation has not been
given much attention yet.
In the present study we did not detect resolvins in any of
the samples. It might be that these compounds are not formed
in quantities high enough to be detected with our method
during the first 24 h after the initiation of the inflammatory
response, or the detection limit of the analytical method was
not sufficient to detect these compounds. The single time-
point approach in the present study is a limitation of the
work, and investigating a broader time range, e.g. studying
multiple time points beyond 24 h after the initiation of
inflammation, might reveal temporal changes in lipid
mediators including resolvins.
The presence of 17-HDoHE (also known as 17-HDHA),
a marker for resolvin synthesis (Poulsen et al. 2008) with
anti-inflammatory properties (Gonza´lez-Pe´riz et al. 2006),
was increased by the FO diets. The FO diets as well as LPS
increased levels of 10,17-DiHDoHE, (also known as pro-
tectin DX) which was previously shown to reduce
inflammation and accelerate its resolution (Serhan et al.
2006). Altogether, the FO diets altered all branches in the
oxylipin metabolome in a way that is largely associated
with suppression of inflammation.
A major finding of this work is that the effects of FO
were also persistent under inflammatory conditions. Mul-
tivariate data analysis revealed that both endocannabinoids
and oxylipins are responsible for separation between diet
groups. Under non-inflammatory conditions, the diet
groups could be primarily separated based on the reduction
of other than n-3 derived endocannabinoids and oxylipins.
In contrast, with LPS treatment, the diet groups were pri-
marily separated by increases in levels of n-3 fatty acid
derived endocannabinoids and oxylipins. The combined
approach of comparing normal versus inflammatory con-
ditions was thus useful in demonstrating that effects of diet
on oxylipins and endocannabinoids are depending on
inflammatory status.
Recent evidence suggested that relatively high intakes of
FO impairs the host’s resistance to microbial infection
(Bonilla et al. 2010; Irons et al. 2003; Snel et al. 2010). In
our study, the mice that had received 3 % FO showed
relatively more severe signs of shock after LPS, and one
mouse from the 3 % FO ? LPS group died shortly before
the end of the experiment. This would be in line with the
notion that high FO intake might impair the host’s resis-
tance to inflammatory stress, or to suppress the capability
to overcome the inflammatory stimulus. We observed that
plasma TBXB2 levels, a compound related to TBXA2
which is involved in vasoconstriction (Sellers and Stallone
2008), was decreased in the 3 % FO group compared to the
1 % FO group, but also by LPS. The combination 3 % FO
and LPS treatment might have caused a decrease in TBXA2
levels below its physiological range, potentially increasing
the risk of inducing excessive vasodilatation and shock.
Alternatively, pre-treatment of rats with a CB1 blocker was
effective in reducing hypotension after LPS administration
(Varga et al. 1998), suggesting that increases in endocan-
nabinoids after LPS might also contribute to the shock
observed for the 3 % FO ? LPS group. Future work
should point out which (combination of) metabolites
account for the impaired resistance in the 3 % FO ? LPS
group. Furthermore, future work should clarify which
intake levels of n-3 fatty acids are beneficial to reduce
symptoms of inflammatory diseases and where the inhibi-
tion of inflammation starts to interfere with an efficient
response to an inflammatory stimulus.
In conclusion, dietary FO caused marked changes in the
n-3 to n-6 balance of the endocannabinoid and oxylipin
metabolomes, with specific effects depending on inflam-
matory status. The effects on metabolites are in line with
the anti-inflammatory effects associated with n-3 fatty acid
intake.
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